Non-antibiotics: Alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries

被引:45
作者
Amaral, Leonard
Viveiros, Miguel
Kristiansen, Jette E.
机构
[1] Univ Nova Lisboa, UPMM, Inst Higiene & Med Trop, Unit Mycobacteriol, P-1349008 Lisbon, Portugal
[2] So Univ Denmark, Sonderborg Syghus, Dept Clin Microbiol, DK-6400 Sonderborg, Denmark
关键词
D O I
10.2174/138945006777709539
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The antibiotic resistance is now common place throughout the globe. Two highly problematic antibiotic resistant infections are those produced by multi-drug resistant Mycobacterium tuberculosis (MDRTB) and methicillin resistant Staplylococcus aureus (MRSA). Although vancomycin is useful for therapy of MRSA, there is now evidence that resistance to this antibiotic is taking place. Intracellular infections of MRSA are very difficult to manage and are recurrent especially when invasive prosthetic devices are employed. This mini-review provides cogent evidence that both intracellular MDRTB and intracellular MRSA can be killed by concentrations of the non-antibiotic phenothiazine, Thioridazine. at concentrations in the medium that are below those present in the plasma of patients treated with this agent. Although thioridazine has been claimed to cause arrhythmias and even sudden death, the frequencies of these episodes are rare and when present, they are related to the patients underlying cardiac status as opposed to the direct effect of the agent itself. The authors do not suggest that thioridazine be used indiscriminately for MDRTB or intracellular infections produced by MRSA. However, there are circumstances where there are no alternative forms of therapy and the patient faces an unfavourable prognosis. For these highly selective and controlled situations. the use of thioridazine in the manner employed for the therapy of psychosis is recommended (compassionate therapy).
引用
收藏
页码:887 / 891
页数:5
相关论文
共 49 条
[1]   RETRACTED: The large-conductance Ca2+-activated K+ channel is essential for innate immunity (Retracted article. See vol. 468, 2010) [J].
Ahluwalia, J ;
Tinker, A ;
Clapp, LH ;
Duchen, MR ;
Abramov, AY ;
Pope, S ;
Nobles, M ;
Segal, AW .
NATURE, 2004, 427 (6977) :853-858
[2]  
Al Zahrani K, 2000, AM J RESP CRIT CARE, V162, P1419, DOI 10.1164/ajrccm.162.4.9912048
[3]   Phenothiazines: potential management of Creutzfeldt-Jacob disease and its variants [J].
Amaral, L ;
Kristiansen, JE .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2001, 18 (05) :411-417
[4]   SYNERGIC EFFECT OF CHLORPROMAZINE ON THE ACTIVITY OF SOME ANTIBIOTICS [J].
AMARAL, L ;
KRISTIANSEN, J ;
LORIAN, V .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 30 (04) :556-558
[5]   Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: Potential use for initial therapy of freshly diagnosed tuberculosis [J].
Amaral, L ;
Kristiansen, JE ;
Abebe, LS ;
Millett, W .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 38 (06) :1049-1053
[6]   Phenothiazines: an alternative to conventional therapy for the initial management of suspected multidrug resistant tuberculosis. A call for studies [J].
Amaral, L ;
Kristiansen, JE .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 14 (03) :173-176
[7]   Phenothiazines: potential alternatives for the management of antibiotic resistant infections of tuberculosis and malaria in developing countries [J].
Amaral, L ;
Viveiros, M ;
Kristiansen, JE .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2001, 6 (12) :1016-1022
[8]   Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis:: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy [J].
Amaral, L ;
Kristiansen, JE ;
Viveiros, M ;
Atouguia, J .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (05) :505-511
[9]   Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis [J].
Bettencourt, MV ;
Bosne-David, S ;
Amaral, L .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 16 (01) :69-71
[10]  
BLAGOVES.VA, 1973, ANTIBIOT MED BIOTEK, V18, P133